Theodore M. Blum

Array ( [id] => 20693953 [patent_doc_number] => 20260125359 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2026-05-07 [patent_title] => HETEROARYL COMPOUNDS AS MULTI-TARGET PROTEIN KINASE INHIBITORS [patent_app_type] => utility [patent_app_number] => 19/433491 [patent_app_country] => US [patent_app_date] => 2025-12-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 63187 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19433491 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20349744 [patent_doc_number] => 20250346596 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-11-13 [patent_title] => GLP-1R Agonist and Therapeutic Method Thereof [patent_app_type] => utility [patent_app_number] => 19/271557 [patent_app_country] => US [patent_app_date] => 2025-07-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29776 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19271557 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20349742 [patent_doc_number] => 20250346594 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-11-13 [patent_title] => GLP-1R Agonist and Therapeutic Method Thereof [patent_app_type] => utility [patent_app_number] => 19/271548 [patent_app_country] => US [patent_app_date] => 2025-07-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29690 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19271548 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20349743 [patent_doc_number] => 20250346595 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-11-13 [patent_title] => GLP-1R Agonist and Therapeutic Method Thereof [patent_app_type] => utility [patent_app_number] => 19/271553 [patent_app_country] => US [patent_app_date] => 2025-07-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29691 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19271553 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20309144 [patent_doc_number] => 20250326773 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-10-23 [patent_title] => MRGPRX2 ANTAGONISTS, PHARMACEUTICAL COMPOSITION INCLUDING MRGPRX2 ANTAGONIST, AND METHOD OF TREATING MRGPRX2-MEDIATED DISEASE OR DISORDER [patent_app_type] => utility [patent_app_number] => 19/249435 [patent_app_country] => US [patent_app_date] => 2025-06-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 128633 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19249435 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20578413 [patent_doc_number] => 12570655 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-03-10 [patent_title] => Cysteine covalent modifiers of AKT1 and uses thereof [patent_app_type] => utility [patent_app_number] => 19/224601 [patent_app_country] => US [patent_app_date] => 2025-05-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 6 [patent_no_of_words] => 113921 [patent_no_of_claims] => 55 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 901 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19224601 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20414114 [patent_doc_number] => 12497384 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-12-16 [patent_title] => Aryl ether-substituted heterocyclic compounds as GLP1R agonists [patent_app_type] => utility [patent_app_number] => 19/218087 [patent_app_country] => US [patent_app_date] => 2025-05-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 59838 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19218087 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20150435 [patent_doc_number] => 20250250273 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-08-07 [patent_title] => AZAINDOLE ROCK INHIBITORS [patent_app_type] => utility [patent_app_number] => 19/094486 [patent_app_country] => US [patent_app_date] => 2025-03-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29109 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 5 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19094486 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20438632 [patent_doc_number] => 12509459 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-12-30 [patent_title] => Inhibitors of NLRP3 inflammasome [patent_app_type] => utility [patent_app_number] => 19/089839 [patent_app_country] => US [patent_app_date] => 2025-03-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 17 [patent_no_of_words] => 58077 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 421 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19089839 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20279311 [patent_doc_number] => 20250304553 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-10-02 [patent_title] => ARYL ETHER-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS GLP1R AGONISTS [patent_app_type] => utility [patent_app_number] => 19/084086 [patent_app_country] => US [patent_app_date] => 2025-03-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 59974 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19084086 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20385409 [patent_doc_number] => 12485118 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-12-02 [patent_title] => Combinations of GLP-1R and THRb agonists and methods of use thereof [patent_app_type] => utility [patent_app_number] => 19/072846 [patent_app_country] => US [patent_app_date] => 2025-03-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 34 [patent_no_of_words] => 44734 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 398 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19072846 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20068517 [patent_doc_number] => 20250206739 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-06-26 [patent_title] => Compounds [patent_app_type] => utility [patent_app_number] => 19/002520 [patent_app_country] => US [patent_app_date] => 2024-12-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 51763 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 88 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19002520 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20329631 [patent_doc_number] => 12459896 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-11-04 [patent_title] => Process for preparing 4-methyl-2-propan-2-yl-pyridine-3-carbonitrile [patent_app_type] => utility [patent_app_number] => 18/988131 [patent_app_country] => US [patent_app_date] => 2024-12-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 13800 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18988131 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20271960 [patent_doc_number] => 12441729 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-10-14 [patent_title] => Process for preparing 7-chloro-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione [patent_app_type] => utility [patent_app_number] => 18/987521 [patent_app_country] => US [patent_app_date] => 2024-12-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7623 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 71 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18987521 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19983975 [patent_doc_number] => 20250122197 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-04-17 [patent_title] => PROCESS FOR RACEMIZING AND ISOLATING ATROPISOMERS OF 7-CHLORO-6-FLUORO-1-(2-ISOPROPYL-4-METHYLPYRIDIN-3-YL)PYRIDO[2,3-D]PYRIMIDINE-2,4(1H,3H)-DIONE [patent_app_type] => utility [patent_app_number] => 18/987607 [patent_app_country] => US [patent_app_date] => 2024-12-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8373 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18987607 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20239006 [patent_doc_number] => 12419308 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-09-23 [patent_title] => Phenylpyrazole insecticide compounds and compositions [patent_app_type] => utility [patent_app_number] => 18/959040 [patent_app_country] => US [patent_app_date] => 2024-11-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18519 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 12 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18959040 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20024838 [patent_doc_number] => 20250163060 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-05-22 [patent_title] => SOLID FREEBASE FORMS OF 5-CHLORO-2-(4-((2-HYDROXY-2-METHYLPROPYL)AMINO)PYRIDO[3,4-D]PYRIDAZIN-1-YL)PHENOL FOR INHIBITING NLRP3 AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/952401 [patent_app_country] => US [patent_app_date] => 2024-11-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30250 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18952401 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20024835 [patent_doc_number] => 20250163057 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-05-22 [patent_title] => DCN-1 MODULATING COMPOUNDS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/935099 [patent_app_country] => US [patent_app_date] => 2024-11-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 182432 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18935099 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20024836 [patent_doc_number] => 20250163058 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-05-22 [patent_title] => MODULATORS OF DCN-1 AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/935253 [patent_app_country] => US [patent_app_date] => 2024-11-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 112840 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18935253 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19931704 [patent_doc_number] => 12304901 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-05-20 [patent_title] => Selective ligands for tau aggregates [patent_app_type] => utility [patent_app_number] => 18/929263 [patent_app_country] => US [patent_app_date] => 2024-10-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 11709 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 5 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18929263 [rel_patent_id] =>[rel_patent_doc_number] =>)